GondolaBio reports positive data from Phase IIa trial of PORT-77

GondolaBio has reported positive results from its Phase IIa GATEWAY study of PORT-77, which aims to treat EPP and XLP. The results indicate PORT-77 was well tolerated, with no serious adverse events or treatment discontinuations. In the study, 19 participants received either a placebo followed by 180mg PORT-77 QD or 300mg BID for four days. Credit: PeopleImages / Shutterstock.com. GondolaBio has reported positive results from its Phase IIa GATEWAY study of PORT-77, an investigational oral ABCG2 inhibitor, which aims to treat erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). The company announced the results on behalf of its affiliate Portal Therapeutics.…

Source: Clinical Trials Arena